BiotechTube

Open-Label ESK-001 + Blinded ESK-001 + Placebo

Phase 3Active
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Plaque Psoriasis

Conditions

Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis

Trial Timeline

Jan 8, 2025 → Nov 1, 2028

NCT ID
NCT06846541

About Open-Label ESK-001 + Blinded ESK-001 + Placebo

Open-Label ESK-001 + Blinded ESK-001 + Placebo is a phase 3 stage product being developed by Alumis for Plaque Psoriasis. The current trial status is active. This product is registered under clinical trial identifier NCT06846541. Target conditions include Plaque Psoriasis, Psoriasis (PsO), Psoriasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06846541Phase 3Active

Competing Products

20 competing products in Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
CT-P55 + EU-approved CosentyxCelltrionPhase 3
77
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
alefaceptAstellas PharmaApproved
85
AlefaceptAstellas PharmaApproved
85
Halobetasol PropionateSun PharmaceuticalPhase 2
52
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
DSXS + PlaceboSun PharmaceuticalPhase 3
77
DSXSSun PharmaceuticalPhase 2
52
DSXS topicalSun PharmaceuticalPhase 2
52
Halobetasol Topical LotionSun PharmaceuticalApproved
85
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Matching PlaceboSun PharmaceuticalPhase 3
77
DSXS1411 + PlaceboSun PharmaceuticalPhase 2
52
Tildrakizumab + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Tildrakizumab Placebo + Etanercept Placebo + Etanercept 50 mgSun PharmaceuticalPhase 3
77
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
77

Other Products from Alumis

ESK-001 + Apremilast + PlaceboPhase 3
72
ESK-001 + Placebo + ApremilastPhase 3
72
ESK-001Phase 2
47
ESK-001Phase 2
47
ESK-001 + PlaceboPhase 2
47